Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States.

Ash Bullement Emma S Knowles Pronabesh DasMahapatra Talaha M Ali Ron Preblick

Published in: PharmacoEconomics - open (2021)

rFVIIIFc may offer a cost-effective option for severe HA patients. Uncertainties owing to the limited evidence base is the main limitation of the study.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
early onset
prognostic factors
patient reported